3 results on '"MA. Astarcioglu"'
Search Results
2. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator.
- Author
-
Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M, Oğuz AE, Gündüz S, Astarcioglu MA, Aykan AÇ, Bayram Z, Biteker M, Kaynak E, Kahveci G, Duran NE, and Yıldız M
- Subjects
- Adult, Female, Heart Diseases epidemiology, Humans, Infusions, Intravenous, Pregnancy, Pregnancy Complications, Cardiovascular epidemiology, Prospective Studies, Thrombosis epidemiology, Time Factors, Treatment Outcome, Young Adult, Heart Diseases drug therapy, Heart Valve Prosthesis adverse effects, Pregnancy Complications, Cardiovascular drug therapy, Thrombolytic Therapy methods, Thrombosis drug therapy, Tissue Plasminogen Activator administration & dosage
- Abstract
Background: Prosthetic valve thrombosis during pregnancy is life-threatening for mother and fetus, and the treatment of this complication is unclear. Cardiac surgery in pregnancy is associated with very high maternal and fetal mortality and morbidity. Thrombolytic therapy has rarely been used in these patients. The aim of this study is to evaluate the safety and efficacy of low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator for the treatment of prosthetic valve thrombosis in pregnant women., Methods and Results: Between 2004 and 2012, tissue-type plasminogen activator was administered to 24 consecutive women in 25 pregnancies with 28 prosthetic valve thrombosis episodes (obstructive, n=15; nonobstructive, n=13). Mean age of the patients was 29±6 years. Thrombolytic therapy sessions were performed under transesophageal echocardiography guidance. The mean dose of tissue-type plasminogen activator used was 48.7±29.5 mg (range, 25-100 mg). All episodes resulted in complete thrombus lysis after thrombolytic therapy. One patient had placental hemorrhage with preterm live birth at the 30th week, and 1 patient had minor bleeding., Conclusions: Low-dose, slow infusion of tissue-type plasminogen activator with repeated doses as needed is an effective therapy with an excellent thrombolytic success rate for the treatment of prosthetic valve thrombosis in pregnant women. This protocol also seems to be safer than cardiac surgery or any alternative medical strategies published to date. Thrombolytic therapy should be considered first-line therapy in pregnant patients with prosthetic valve thrombosis.
- Published
- 2013
- Full Text
- View/download PDF
3. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial.
- Author
-
Özkan M, Gündüz S, Biteker M, Astarcioglu MA, Çevik C, Kaynak E, Yıldız M, Oğuz E, Aykan AÇ, Ertürk E, Karavelioğlu Y, Gökdeniz T, Kaya H, Gürsoy OM, Çakal B, Karakoyun S, Duran N, and Özdemir N
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Chi-Square Distribution, Drug Administration Schedule, Female, Fibrinolytic Agents adverse effects, Heart Valve Prosthesis Implantation adverse effects, Hospital Mortality, Humans, Infusions, Parenteral, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Predictive Value of Tests, Prospective Studies, Prosthesis Design, Risk Factors, Streptokinase adverse effects, Thrombolytic Therapy adverse effects, Thrombolytic Therapy mortality, Thrombosis diagnostic imaging, Thrombosis etiology, Thrombosis mortality, Time Factors, Tissue Plasminogen Activator adverse effects, Treatment Outcome, Turkey, Young Adult, Echocardiography, Transesophageal, Fibrinolytic Agents administration & dosage, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Prosthesis Failure, Streptokinase administration & dosage, Thrombolytic Therapy methods, Thrombosis drug therapy, Tissue Plasminogen Activator administration & dosage
- Abstract
Objectives: The aim of this prospective study was to identify the most effective and safest regimen among different thrombolytic treatment strategies., Background: The best treatment strategies for prosthetic valve thrombosis have been controversial., Methods: Transesophageal echocardiography-guided thrombolytic treatment was administered to 182 consecutive patients with prosthetic valve thrombosis in 220 different episodes (156 women; mean age, 43.2 ± 13.06 years) between 1993 and 2009 at a single center. These regimens chronologically included rapid (Group I), slow (Group II) streptokinase, high-dose (100 mg) tissue plasminogen activator (t-PA) (Group III), a half-dose (50 mg) and slow infusion (6 h) of t-PA without bolus (Group IV), and a low dose (25 mg) and slow infusion (6 h) of t-PA without bolus (Group V). The endpoints were thrombolytic success, in-hospital mortality, and nonfatal complication rates., Results: The overall success rate in the whole series was 83.2%; it did not differ significantly among Groups I through V (68.8%, 85.4%, 75%, 81.5%, and 85.5%, respectively; p = 0.46). The overall complication rate in the whole series was 18.6%. Although the overall complication rate was similar among Groups I through IV (37.5%, 24.4 %, 33.3%, and 29.6%, respectively; p > 0.05 for each comparison), it was significantly lower in Group V (10.5%, p < 0.05 for each). The combined rates of mortality and nonfatal major complications were also lower in Group V than in the other groups, with all differences significant except for comparison of Groups IV and V. By multivariate analysis, the predictors of combined mortality plus nonfatal major complications were any thrombolytic therapy regimen other than Group V (odds ratios for Groups I through IV: 8.2, 3.8, 8.1, and 4.1, respectively; p < 0.05 for each) and a history of stroke/transient ischemic attack (odds ratio: 3.5, p = 0.011). In addition, there was no mortality in Group V., Conclusions: Low-dose slow infusion of t-PA repeated as needed without a bolus provides effective and safe thrombolysis in patients with prosthetic valve thrombosis. (Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis; NCT01451320)., (Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.